| Attenuation of microRNA-126 Expression That Drives CD34+38− Stem/Progenitor Cells in Acute Myeloid Leukemia Leads to Tumor Eradication DC De Leeuw, F Denkers, MC Olthof, AP Rutten, W Pouwels, ... Cancer research 74 (7), 2094-2105, 2014 | 112 | 2014 |
| A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin W van den Ancker, TM Westers, DC de Leeuw, YFCM van der Veeken, ... Cytometry Part B: Clinical Cytometry 84 (2), 114-118, 2013 | 61 | 2013 |
| MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemia DC de Leeuw, W van den Ancker, F Denkers, RX de Menezes, ... Clinical Cancer Research 19 (8), 2187-2196, 2013 | 58 | 2013 |
| IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival HJMP Verhagen, DC De Leeuw, MGM Roemer, F Denkers, W Pouwels, ... Cell death & disease 5 (6), e1300-e1300, 2014 | 35 | 2014 |
| Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies MS Griffioen, DC de Leeuw, JJWM Janssen, L Smit Cancers 14 (14), 3456, 2022 | 24 | 2022 |
| MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia DC De Leeuw, H Verhagen, F Denkers, FG Kavelaars, PJM Valk, ... Leukemia 30 (3), 742-746, 2016 | 21 | 2016 |
| Older patients with acute myeloid leukemia deserve individualized treatment DC de Leeuw, GJ Ossenkoppele, JJWM Janssen Current oncology reports 24 (11), 1387-1400, 2022 | 19 | 2022 |
| IGFBP7 induces differentiation and loss of survival of human acute myeloid leukemia stem cells without affecting normal hematopoiesis HJMP Verhagen, N van Gils, T Martiañez, A van Rhenen, A Rutten, ... Cell reports 25 (11), 3021-3035. e5, 2018 | 19 | 2018 |
| Specific depletion of leukemic stem cells: Can microRNAs make the difference? T Martiáñez Canales, DC De Leeuw, E Vermue, GJ Ossenkoppele, L Smit Cancers 9 (7), 74, 2017 | 10 | 2017 |
| Optimizing antiviral dosing for HSV and CMV treatment in immunocompromised patients DW Huntjens, JA Dijkstra, LN Verwiel, M Slijkhuis, P Elbers, MRA Welkers, ... Pharmaceutics 15 (1), 163, 2023 | 8 | 2023 |
| Case report: Candida krusei spondylitis in an immunocompromised patient AJC Overgaauw, DC de Leeuw, SP Stoof, K van Dijk, JCJ Bot, ... BMC Infectious Diseases 20 (1), 739, 2020 | 8 | 2020 |
| Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial LL Ngai, D Hanekamp, F Janssen, J Carbaat-Ham, MAMA Hofland, ... Blood, The Journal of the American Society of Hematology 141 (21), 2657-2661, 2023 | 7 | 2023 |
| An open-label, first-in-human, dose-escalation study of SAR443579 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid … AS Stein, A Bajel, S Fleming, M Jongen-Lavrencic, S Garciaz, A Maiti, ... Blood 140 (Supplement 1), 7476-7477, 2022 | 6 | 2022 |
| High-dose melphalan in 1 day versus over 2 days followed by autologous stem cell transplantation as consolidation treatment in patients with multiple myeloma M Aydin, MW Tang, M Wondergem, DC de Leeuw, JJ Wegman, ... Blood 138, 3944, 2021 | 5 | 2021 |
| Challenging diagnosis in a patient with clear lymphoid immunohistochemical features and myeloid morphology: Mixed phenotype acute leukemia with erythrophagocytosis DC de Leeuw, W van den Ancker, TM Westers, AH Loonen, SL Bhola, ... Leukemia research 35 (5), 693-696, 2011 | 4 | 2011 |
| Covalent menin inhibitor Bmf-219 in patients with relapsed or refractory (R/R) acute leukemia (AL): preliminary phase 1 data from the Covalent-101 study J Lancet, F Ravandi, P Montesinos, JC Barrientos, T Badar, A Alegre, ... Blood 142, 2916, 2023 | 3 | 2023 |
| Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia JM Tettero, ME Heidinga, TR Mocking, G Fransen, A Kelder, WJ Scholten, ... Leukemia, 1-10, 2024 | 2 | 2024 |
| First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia … A Bajel, S Garciaz, P Desai, GA Huls, A Maiti, M Jongen-Lavrencic, ... Blood 142, 3474, 2023 | 2 | 2023 |
| EP0042, a dual FLT3 and Aurora kinase inhibitor: preliminary results of an ongoing phase I/IIa first in human study in patients with relapsed/refractory acute myeloid leukemia D Taussig, J O'Nions, M Jongen-Lavrencic, JJ Janssen, DC de Leeuw, ... Blood 140 (Supplement 1), 6222-6223, 2022 | 2 | 2022 |
| Transient seizure-induced sodium increase camouflaging a symptomatic hyponatremia DC de Leeuw, AJ Kooter BMJ Case Reports CP 13 (1), e229328, 2020 | 2 | 2020 |
